GSK Announced ViiV Healthcare and MPP are Actively Negotiating Voluntary Licensing Terms to Help Widen Access to HIV Prevention Measure
GSK Announced ViiV Healthcare and MPP are Actively Negotiating Voluntary Licensing Terms to Help Widen Access to HIV Prevention Measure
葛蘭素史克宣佈ViiV Healthcare和MPP正在積極談判自願許可條款,以幫助擴大獲得艾滋病毒預防措施的機會
ViiV Healthcare has today announced that it is committing to license its patents relating to cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP) and is entering into negotiation on voluntary licensing terms with the UN-backed Medicines Patent Pool (MPP). ViiV Healthcare and MPP are working to agree terms and execute a voluntary licence as quickly as possible to help enable at scale access to cabotegravir LA for PrEP in low- and middle-income countries. This builds on a long-standing partnership between ViiV Healthcare and MPP which has been highly successful in facilitating the manufacture and sale...
ViiV Healthcare has today announced that it is committing to license its patents relating to cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP) and is entering into negotiation on voluntary licensing terms with the UN-backed Medicines Patent Pool (MPP). ViiV Healthcare and MPP are working to agree terms and execute a voluntary licence as quickly as possible to help enable at scale access to cabotegravir LA for PrEP in low- and middle-income countries. This builds on a long-standing partnership between ViiV Healthcare and MPP which has been highly successful in facilitating the manufacture and sale...
ViiV Healthcare今天宣佈,它正在承諾許可其與用於HIV暴露前預防(PrEP)的Cabotegravir長效(LA)相關的專利,並正在與聯合國支持的藥品專利庫(MPP)就自願許可條款進行談...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
搶先評論
0 0 0
讚好勁正笑哭社會社會Emm惨惨嬲嬲
輕觸選擇心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧
點擊這裡與好友分享
暫無評論,快來留言吧!